Alexa

Glaxo says FDA gave approval to allergy nasal spray

Glaxo says FDA gave approval to allergy nasal spray

GlaxoSmithKline PLC said Monday that the U.S. Food and Drug Administration approved its VeramystNasal spray to treat seasonal and year-round allergy symptoms in adults and children 2 years of age and older.
Veramyst will be available by prescription in the U.S. by late May, the company said in a statement.
This is the first regulatory approval of fluticasone furoate nasal spray, which is currently under regulatory review under the trade name Allermist in Japan and under the trade name Avamys in Europe, Canada, Australia and other international markets.
Veramyst targets overall nasal allergy symptoms, which include nasal congestion, sneezing, itchy nose and runny nose.
GlaxoSmithKline shares climbed 0.7 percent to 1,450 pence (US$28.97; euro21.23) in London.


Updated : 2021-03-07 20:05 GMT+08:00